Evidence map›Paper›PMID 33791222›Full record

ArticleFrontiers in oncology2021

Micro1278 Leads to Tumor Growth Arrest, Enhanced Sensitivity to Oxaliplatin and Vitamin D and Inhibits Metastasis

Weidong Lin, Heng Zou, Jinggang Mo, Chong Jin, Hao Jiang, Chengyang Yu, Zufu Jiang, Yusha Yang, Bin He, Kunpeng Wang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. International journal of general medicine · 2022
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Weidong LinDepartment of General Surgery, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Heng ZouDepartment of General Surgery, Second Xiangya Hospital, Central South University, Changsha, China.
Jinggang MoDepartment of General Surgery, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Chong JinDepartment of General Surgery, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Hao JiangDepartment of General Surgery, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Chengyang YuDepartment of General Surgery, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Zufu JiangDepartment of General Surgery, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Yusha YangDepartment of General Surgery, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Bin HeDepartment of General Surgery, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Kunpeng WangDepartment of General Surgery, Taizhou Central Hospital (Taizhou University Hospital), Taizhou, China.
Taizhou University · CNTaizhou Central Hospital · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is the most common cancer type in the digestive tract. Chemotherapy drugs, such as oxaliplatin, are frequently administered to CRC patients diagnosed with advanced or metastatic disease. A better understanding of the molecular mechanism underlying CRC tumorigenesis and the identification of optimal biomarkers for assessing chemotherapy sensitivity are essential for the treatment of CRC. Various microRNAs, constituting class of non-coding RNAs with 20-22 nucleotides, have served as oncogenes or tumor suppressors in CRC. We analyzed miR-1278 expression in clinical samples by qRT-PCR. We then explored the role of miR-1278 in CRC growth

Indexed as

BTG2colorectal cancerCYP24A1KIF5Bmicro1278oxaliplatinvitamin D

Identifiers

PMID33791222
PMCPMC8006274
OpenAlexW3135237304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.